Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
- PMID: 30850440
- PMCID: PMC6448453
- DOI: 10.1212/WNL.0000000000007242
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
Abstract
Objective: To revise the 1999 Airlie House consensus guidelines for the design and implementation of preclinical therapeutic studies and clinical trials in amyotrophic lateral sclerosis (ALS).
Methods: A consensus committee comprising 140 key members of the international ALS community (ALS researchers, clinicians, patient representatives, research funding representatives, industry, and regulatory agencies) addressed 9 areas of need within ALS research: (1) preclinical studies; (2) biological and phenotypic heterogeneity; (3) outcome measures; (4) disease-modifying and symptomatic interventions; (5) recruitment and retention; (6) biomarkers; (7) clinical trial phases; (8) beyond traditional trial designs; and (9) statistical considerations. Assigned to 1 of 8 sections, committee members generated a draft set of guidelines based on a "background" of developing a (pre)clinical question and a "rationale" outlining the evidence and expert opinion. Following a 2-day, face-to-face workshop at the Airlie House Conference Center, a modified Delphi process was used to develop draft consensus research guidelines, which were subsequently reviewed and modified based on comments from the public. Statistical experts drafted a separate document of statistical considerations (section 9).
Results: In this report, we summarize 112 guidelines and their associated backgrounds and rationales. The full list of guidelines, the statistical considerations, and a glossary of terms can be found in data available from Dryad (appendices e-3-e-5, doi.org/10.5061/dryad.32q9q5d). The authors prioritized 15 guidelines with the greatest potential to improve ALS clinical research.
Conclusion: The revised Airlie House ALS Clinical Trials Consensus Guidelines should serve to improve clinical trial design and accelerate the development of effective treatments for patients with ALS.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House "Therapeutic Trials in ALS" Workshop Contributors.J Neurol Sci. 1995 May;129 Suppl:1-10. J Neurol Sci. 1995. PMID: 7595596 Review. No abstract available.
-
Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research.J Neurol Sci. 1999 Oct 31;169(1-2):2-12. doi: 10.1016/s0022-510x(99)00209-9. J Neurol Sci. 1999. PMID: 10540001 Review.
-
ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment.Neurology. 2019 Jul 9;93(2):66-71. doi: 10.1212/WNL.0000000000007695. Epub 2019 Jun 6. Neurology. 2019. PMID: 31171646 Free PMC article. Review.
-
Clinical trials in amyotrophic lateral sclerosis.Curr Opin Neurol. 2019 Oct;32(5):758-763. doi: 10.1097/WCO.0000000000000731. Curr Opin Neurol. 2019. PMID: 31335338 Review.
Cited by
-
Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers.Mol Neurodegener. 2020 Oct 15;15(1):58. doi: 10.1186/s13024-020-00406-3. Mol Neurodegener. 2020. PMID: 33059698 Free PMC article. Review.
-
Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis.J Neurol Neurosurg Psychiatry. 2022 Apr;93(4):422-435. doi: 10.1136/jnnp-2021-327503. Epub 2022 Feb 1. J Neurol Neurosurg Psychiatry. 2022. PMID: 35105727 Free PMC article. Review.
-
Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis.Lancet Neurol. 2022 May;21(5):480-493. doi: 10.1016/S1474-4422(21)00465-8. Epub 2022 Mar 22. Lancet Neurol. 2022. PMID: 35334233 Free PMC article. Review.
-
The landscape of neurophysiological outcome measures in ALS interventional trials: A systematic review.Clin Neurophysiol. 2022 May;137:132-141. doi: 10.1016/j.clinph.2022.02.020. Epub 2022 Mar 8. Clin Neurophysiol. 2022. PMID: 35313253 Free PMC article.
-
Measuring disease progression in primary lateral sclerosis.Amyotroph Lateral Scler Frontotemporal Degener. 2020 Nov;21(sup1):59-66. doi: 10.1080/21678421.2020.1837179. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 33602016 Free PMC article.
References
-
- Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology Committee on Research. J Neurol Sci 1999;169:2–12. - PubMed
-
- Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 2014;13:1127–1138. - PubMed
-
- Writing Group; Edaravone (MCI-186) ALS Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505–512. - PubMed
-
- Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science 2014;345:1247125. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous